FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients with tuberculosis or other severe infections such as sepsis, abscesses and opportunistic infections (see section 4.4).
Croatian: Bolesnici s tuberkulozom ili drugim teškim infekcijama poput sepse, apscesa i oportunističkih infekcija (vidjeti dio 4.4).
English: Remsima subcutaneous formulation is not intended for intravenous administration and should be administered via a subcutaneous injection only.
Croatian: Supkutana formulacija lijeka Remsima nije namijenjena za intravensku primjenu i smije se davati samo putem supkutane injekcije.
English: A clinical study in patients with moderate to severe psoriasis was designed to assess the efficacy and safety of long-term maintenance therapy versus re-treatment with an induction regimen of infliximab (maximum of four infusions at 0, 2, 6 and 14 weeks) following disease flare.
Croatian: Provedeno je kliničko ispitivanje bolesnika s umjerenom do teškom psorijazom kako bi se ocijenile djelotvornost i sigurnost dugotrajne terapije održavanja u odnosu na ponovno davanje uvodnog režima liječenja lijekom infliksimab (najviše četiri infuzije u 0., 2., 6. i 14. tjednu) nakon ponovnog izbijanja bolesti.
English: Full instructions for use are provided in the package leaflet.
Croatian: Potpune upute za uporabu nalaze se u uputi o lijeku.
English: In the REACH study, infections were reported in 56.3% of randomised subjects treated with infliximab.
Croatian: Infekcije U ispitivanju REACH infekcije su prijavljene u 56,3% randomiziranih ispitanika liječenih infliksimabom.
English: Pack sizes of 1, 2, 3, 4, 5 vials.
Croatian: Remsima pakiranja sadrže 1, 2, 3, 4 ili 5 bočica.
English: If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with infliximab and is positive for antibodies against double-stranded DNA, further treatment with infliximab must not be given (see section 4.8).
Croatian: Ako bolesnik nakon liječenja infliksimabom razvije simptome koji ukazuju na sindrom sličan lupusu i ako ima pozitivan nalaz protutijela na dvolančanu DNK, ne smije nastaviti liječenje infliksimabom (vidjeti dio 4.8).
English: • You should avoid getting pregnant when you are being treated with Remsima and for 6 months after you stop being treated with it.
Croatian: • Potrebno je izbjegavati trudnoću tijekom liječenja lijekom Remsima i 6 mjeseci nakon završetka liječenja.
English: b CDAI <150 at both Week 30 and 54 and not receiving corticosteroids in the 3 months prior to
Croatian: b CDAI < 150 i u 30. i u 54. tjednu, bez uzimanja kortikosteroida tijekom 3 mjeseca prije 54. tjedna u bolesnika koji su primali kortikosteroide na početku ispitivanja.
English: Tel: +370 5231 4658 vilnius@egis.lt
Croatian: Tel: +370 5231 4658 vilnisu@egis.lt
English: months prior to enrolment and were to remain on stable doses throughout the study.
Croatian: tijekom 6 mjeseci prije uključenja u ispitivanje i trebali su nastaviti s uzimanjem istih doza tijekom čitavog ispitivanja.
English: • Some patients who have received TNF-blockers, including infliximab have developed a rare type of cancer called hepatosplenic T-cell lymphoma.
Croatian: • U nekih bolesnika koji su liječeni TNF-blokatorima uključujući infliksimab razvio se rijedak oblik raka zvan hepatosplenički limfom T-stanica.
English: • Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)
Croatian: • pogoršanje bolesti koja se zove dermatomiozitis (očituje se kao osip kože sa slabošću mišića) • srčani udar
English: • Treatment with TNF blockers such as Remsima may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life-threatening in some cases.
Croatian: • Liječnik Vas treba testirati na virus hepatitisa B. • Liječenje TNF-blokatorima kao što je Remsima može izazvati ponovnu aktivaciju virusa hepatitisa B u bolesnika koji nose taj virus, što u nekim slučajevima može ugroziti život.
English: Local injection site reactions
Croatian: Lokalne reakcije na mjestu injekcije
English: Doing so may result in a needle stick injury.
Croatian: Ako to učinite možete se ubosti i ozlijediti.
English: Pharmacotherapeutic group: immunosuppressants, tumour necrosis factor alpha (TNFα) inhibitors, ATC code: L04AB02
Croatian: Farmakoterapijska skupina: Imunosupresivi, inhibitori faktora nekroze tumora alfa (TNFα), ATK oznaka: L04AB02
English: 102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were BASDAI 50 responders.
Croatian: 102. tjednu infliksimab je i dalje primalo 49 ispitanika, od kojih je 30 (61%) imalo klinički odgovor
English: The incidence of localised injection site reactions (e.g. injection site erythema, pain, pruritus and swelling) was 17.6 per 100 patient-years in the Remsima subcutaneous group (from Week 6) and 21.4 per 100 patient-years in those who switched to Remsima subcutaneous administration (from Week 30).
Croatian: Incidencija lokaliziranih reakcija na mjestu injekcije (npr. eritem na mjestu injekcije, bol, pruritus i oticanje) bio je 17,6 na 100 bolesnik-godina u grupi liječenoj lijekom Remsima supkutano (od 6. tjedna) i 21,4 na 100 bolesnik-godina u grupi koja je prešla na lijek Remsima supkutano (od 30.
English: Agranulocytosis (including infants exposed in utero to infliximab), thrombotic thrombocytopenic purpura, pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.
Croatian: Agranulocitoza (uključujući dojenčad izloženu infliksimabu in utero), trombotička trombocitopenična purpura, pancitopenija, hemolitička anemija, idiopatska trombocitopenična purpura
English: Mean ± SDc a control = All patients had active RA despite treatment with stable methotrexate doses for 6 months prior to enrolment and were to remain on stable doses throughout the study.
Croatian: Prosječna vrijednost ± SDc a kontrolna skupina = svi su bolesnici imali aktivni reumatoidni artritis usprkos liječenju ustaljenim dozama metotreksata tijekom 6 mjeseci prije uključenja u ispitivanje i trebali su nastaviti s uzimanjem istih doza tijekom čitavog ispitivanja.
English: The infusion solution has to be administered over a period of not less than the infusion time recommended (see section 3).
Croatian: Otopina za infuziju mora se primijeniti tijekom razdoblja koje ne smije biti kraće od preporučenog (vidjeti dio 3).
English: Gastrointestinal haemorrhage, diarrhoea, dyspepsia, gastroesophageal reflux, constipation
Croatian: gastrointestinalno krvarenje, proljev, dispepsija, gastroezofagealni refluks, konstipacija
English: Placebo → Infliximab
Croatian: Placebo → infliksimab
English: ACR 70 response* PASI response (% of patients)b N
Croatian: Odgovor ACR 20* Odgovor ACR 50* Odgovor ACR 70* PASI odgovor (% bolesnika)b
English: For intravenous use after reconstitution and dilution
Croatian: Za intravensku primjenu nakon rekonstitucije i razrjeđivanja.
English: There are no known side effects of having too much of Remsima.
Croatian: Nisu poznate nuspojave kod primjene prevelike količine lijeka Remsima.
English: The primary endpoint of the study was corticosteroid-free clinical remission at week 26, defined as patients in clinical remission (CDAI of <150) who, for at least 3 weeks, had not taken oral systemic corticosteroids (prednisone or equivalent) or budesonide at a dose >6 mg/day.
Croatian: Primarna mjera ishoda ispitivanja bila je klinička remisija bez primjene kortikosteroida u 26. tjednu, što je značilo da bolesnik u kliničkoj remisiji (CDAI < 150) najmanje 3 tjedna nije uzimao peroralne sustavne kortikosteroide (prednizon ili slično) ni budezonid u dozi od > 6 mg/dan.
English: Remsima will generally be stored by the health professionals.
Croatian: Kako čuvati lijek Remsima Lijek Remsima će u pravilu čuvati zdravstveni radnici.
English: If you miss a dose of Remsima for up to 7 days, after the original scheduled dose, you should take the missed dose immediately.
Croatian: Ako je od propuštene doze lijeka Remsima prošlo do 7 dana, trebali biste odmah uzeti propuštenu dozu.
English: In a Phase II study aimed at evaluating infliximab in CHF, higher incidence of mortality due to worsening of heart failure were seen in patients treated with infliximab, especially those treated with the higher dose of 10 mg/kg (i.e. twice the maximum approved dose).
Croatian: U kliničkom ispitivanju faze II s ciljem procjene učinka lijeka infliksimab na kongestivno zatajenje srca uočena je veća incidencija mortaliteta uslijed pogoršanja srčane funkcije u bolesnika liječenih lijekom infliksimab, osobito u onih koji su primali dozu veću od 10 mg/kg (tj. dvostruko veću od maksimalne odobrene doze).
English: Almost all patients had also received medicines containing azathioprine or mercaptopurine in addition to TNF-blockers.
Croatian: Skoro svi bolesnici također su uzimali lijekove koji sadrže azatioprin ili 6-merkaptopurin s TNF-blokatorom.
English: The combination of infliximab with other biological therapeutics used to treat the same conditions as infliximab, including anakinra and abatacept, is not recommended (see section 4.4).
Croatian: Ne preporučuje se primjena infliksimaba u kombinaciji s drugim biološkim lijekovima koji se primjenjuju za liječenje istih stanja kao i infliksimab, uključujući anakinru i abatacept (vidjeti dio 4.4) Ne preporučuje se istodobna primjena živih cjepiva s infliksimabom.
English: b. Remove the pen from the carton stored in your refrigerator.
Croatian: b. Izvadite pakiranje Remsima štrcaljke koje ste čuvali u hladnjaku.
English: Infliximab was studied in a clinical study in 120 patients (age range: 4-17 years old) with active juvenile rheumatoid arthritis despite methotrexate.
Croatian: Kliničko ispitivanje lijeka infliksimab provedeno je u 120 bolesnika (dobni raspon: 4-17 godina) s aktivnim juvenilnim reumatoidnim artritisom usprkos liječenju metotreksatom.
English: Upper respiratory tract infection, sinusitis
Croatian: infekcija gornjih dišnih puteva, sinusitis
English: • It is important that you tell your baby's doctors and other healthcare professionals about your Remsima use before your baby is given any vaccine.
Croatian: • Važno je obavijestiti liječnika Vašeg djeteta i druge zdravstvene radnike o Vašem primanju lijeka Remsima prije nego što Vaše dijete primi bilo koje cjepivo.
English: Remsima treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of conditions for which Remsima is indicated.
Croatian: Liječenje lijekom Remsima uvodi se i provodi pod nadzorom liječnika specijaliste s iskustvom u dijagnosticiranju i liječenju stanja za koja je Remsima indicirana.
English: There is limited safety experience of infliximab treatment in patients who have undergone surgical procedures, including arthroplasty.
Croatian: Ograničena su iskustva o sigurnosti primjene lijeka infliksimab u bolesnika podvrgnutih kirurškim zahvatima, uključujući artroplastiku.
English: a. Pull the olive green cap straight off and set it aside.
Croatian: Povucite maslinastozeleni zatvarač ravno i odložite ga na stranu
English: • Remsima 120 mg solution for injection is administered by injection under the skin (subcutaneous use) only.
Croatian: • Remsima 120 mg otopina za injekciju daje se samo putem injekcije pod kožu (supkutano).
English: Also at week 4, 13/27 (48%) of infliximab-treated patients achieved a clinical remission (CDAI <150) vs. 1/25 (4%) of placebo-treated patients.
Croatian: Također, u 4. je tjednu 13 od 27 (48%) bolesnika liječenih infliksimabom postiglo kliničku remisiju bolesti (CDAI < 150), naspram jednog od 25 (4%) bolesnika koji su primili placebo.
English: In the infliximab group, the mean change in total modified vdH-S score remained below 0 at the week 54 timepoint.
Croatian: Heijdeu modificiranoj Sharpovoj bodovnoj skali ostala je ispod 0 u 54. tjednu.
English: If you are given too much Remsima
Croatian: Ako primite previše lijeka Remsima
English: Table 8 Effects on clinical response, clinical remission and mucosal healing at Weeks 8 and 30.
Croatian: Učinci na klinički odgovor, kliničku remisiju i cijeljenje sluznice u 8. i 30. tjednu.
English: How to use Remsima Rheumatoid arthritis
Croatian: Kako primjenjivati lijek Remsima Reumatoidni artritis
English: Week 50 a p <0.001, for each infliximab treatment group vs. control.
Croatian: 50. tjedan a p < 0,001 za svaku skupinu liječenu infliksimabom u odnosu na kontrolnu skupinu.
English: After administration of infliximab 120 mg subcutaneously every 2 weeks (from Week 6 after 2 doses of intravenous infliximab at Weeks 0 and 2) to patients with active rheumatoid arthritis who were concomitantly treated with MTX, the median (CV%) Ctrough level at Week 22 was 12.8 µg/mL
Croatian: Nakon supkutano primjenjenog infliksimaba od 120 mg svaka 2 tjedna (od 6. tjedna nakon dvije doze intravenskog infliksimaba u 0. i 2. tjednu) bolesnicima s aktivnim reumatoidnim artritisom koji su usporedno liječeni s MTX-om, srednja (CV%) Ctrough razina u 22. tjednu bila je 12,8 µg/ml (80,1 %).
English: Peripheral ischaemia, thrombophlebitis, haematoma
Croatian: periferna ishemija, tromboflebitis, hematom
English: Periodic screening should continue in women treated with infliximab, including those over 60 years of age.
Croatian: Potrebno je nastaviti s periodičkim probirnim pregledima žena liječenih infliksimabom, uključujući i one starije od
English: • The outer area of the upper arms (caregiver ONLY).
Croatian: • vanjsku stranu nadlaktice (primjenjuje SAMO njegovatelj).
English: It is recommended that the conduct of these tests should be recorded in the patient reminder card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
Croatian: Potrebno je upozoriti na rizik lažno negativnih tuberkulinskih testova, osobito u teško bolesnih i imunokompromitiranih bolesnika.
English: Lower respiratory tract infection (e.g. bronchitis, pneumonia), dyspnoea, epistaxis
Croatian: infekcija donjih dišnih puteva (npr. bronhitis, pneumonija), dispneja, epistaksa
English: At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p<0.001).
Croatian: U 54 je tjedana klinički odgovor imalo 44,9% bolesnika u objema skupinama liječenima infliksimabom, u odnosu na19,8% ispitanika u skupini koja je primala placebo (p < 0,001).
English: • Do not use the syringe if it has been dropped or is visibly damaged.
Croatian: • Nemojte primijeniti štrcaljku ako je pala ili su na njoj vidljiva oštećenja.
English: It is important to check the product labels to ensure that the correct formulation is being given as prescribed.
Croatian: Važno je provjeriti navode na pakiranju lijeka kako biste osigurali da se primjenjuje pravi oblik lijeka, u skladu s onim što je liječnik propisao.
English: Store at 2°C - 8°C.
Croatian: Čuvati na temperaturi od 2°C - 8°C.
English: Cases of transient visual loss occurring during or within 2 hours of infliximab infusion have been reported.
Croatian: Prijavljeni su slučajevi prolaznog gubitka vida koji su se javljali tijekom ili do 2 sata nakon primanja infuzije lijeka infliksimab.
English: a. Pull the cap straight off and set it aside.
Croatian: Povucite zatvarač ravno i odložite ga na stranu.
English: Following administration of 5 mg/kg infliximab every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUCss) in paediatric patients aged 6 years to 17 years was approximately 20% lower than the predicted median steady-state medicinal product exposure in adults.
Croatian: 5 mg/kg svakih 8 tjedana, predviđena izloženost infliksimabu u stanju dinamičke ravnoteže (područje pod krivuljom koncentracija-vrijeme u stanju dinamičke ravnoteže, AUCss) u pedijatrijskih bolesnika u dobi od 6 do 17 godina bila je približno 20% niža nego predviđena izloženost u stanju dinamičke ravnoteže u odraslih.
English: The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing infliximab in all subsets of the paediatric population in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja referentnog lijeka koji sadrži infliksimab u svim podskupinama pedijatrijske populacije u reumatoidnom artritisu, juvenilnom idiopatskom artritisu, psorijatičnom artritisu, ankilozantnom spondilitisu i psorijazi (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Please read the Remsima ‘Package Leaflet' carefully before you start using this medicine.
Croatian: Pažljivo pročitajte uputu o lijeku za lijek Remsima prije nego počnete primati ovaj lijek.
English: In an exploratory clinical study evaluating the use of infliximab in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies were reported in infliximabtreated patients compared with control patients.
Croatian: U eksplorativnom kliničkom ispitivanju u kojem se ocjenjivala primjena lijeka infliksimab u bolesnika sa srednje teškom do teškom kroničnom opstruktivnom plućnom bolešću (KOPB), prijavljeno je više slučajeva zloćudnih bolesti u bolesnika liječenih lijekom infliksimab nego u bolesnika u kontrolnoj skupini.
English: However, before Remsima is given to you, it is mixed with a solution that contains sodium.
Croatian: prije prije primjene lijek Remsima, se pomiješa s otopinom koja sadrži natrij.
English: In clinical studies with infliximab in which 5,780 patients were treated, representing 5,494 patient years, 5 cases of lymphomas and 26 non-lymphoma malignancies were detected as compared with no lymphomas and 1 non-lymphoma malignancy in 1,600 placebo-treated patients representing 941 patient years.
Croatian: U kliničkim ispitivanjima s infliksimabom u kojima je liječeno 5780 bolesnika, što predstavlja ukupno 5494 bolesnik-godina, otkriveno je 5 slučajeva limfoma i 26 slučajeva zloćudnih bolesti koje nisu bili limfomi, u odnosu na niti jedan slučaj limfoma i jedan slučaj zloćudne bolesti koja nije bila limfom u
English: If you miss a dose of Remsima for 8 days or more, after the original scheduled dose, you should not take the missed dose.
Croatian: Ako je od propuštene doze lijeka Remsima prošlo 8 dana ili više, nemojte uzeti propuštenu dozu.
English: Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) treated with TNF-blocking agents (initiation of therapy ≤18 years of age), including infliximab in the post-marketing setting.
Croatian: Zloćudne bolesti, neke sa smrtnim ishodom, prijavljene su u djece, adolescenata i mladih odraslih osoba (do 22 godine starosti) koji su liječeni TNF-blokatorima (liječenje započeto u dobi
English: Inspect the medicine (see Figure B).
Croatian: Provjerite lijek (vidjeti Sliku B).
English: In addition, post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with infliximab with the vast majority of cases occurring in Crohn's disease and ulcerative colitis, and most of whom were adolescent or young adult males (see section 4.4).
Croatian: Nadalje, nakon stavljanja u promet prijavljeni su slučajevi hepatospleničkog limfoma T-stanica u bolesnika liječenih lijekom infliksimab, s time da se većina slučajeva javila u bolesnika s Crohnovom bolešću i ulceroznim kolitisom i to većinom u adolescenata i mlađih odraslih muškaraca (vidjeti dio 4.4).
English: Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within the first 12 weeks of treatment (see section 5.1).
Croatian: Treba pomno razmotriti nastavak liječenja u bolesnika u kojih nema dokaza o koristi terapije u prvih 12 tjedana liječenja (vidjeti dio 5.1).
English: • Lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes).
Croatian: • Lihenoidne reakcije (crveno-ljubičasti kožni osip sa svrbežom i/ili bijelo-sive crte slične nitima na sluznici.
English: • Do not breast-feed when you are being treated with Remsima or for 6 months after your last treatment with Remsima.
Croatian: • Nemojte dojiti dok se liječite lijekom Remsima niti 6 mjeseci nakon posljednje doze lijeka Remsima.
English: Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common
Croatian: Unutar klasifikacije organskih sustava, nuspojave su navedene prema sljedećim kategorijama učestalosti pojavljivanja:
English: • Patients taking Remsima may have an increased risk of developing lymphoma or another cancer.
Croatian: • Bolesnici koji uzimaju lijek Remsima mogu imati povećan rizik za razvoj limfoma ili neke druge vrste raka.
English: Remsima contains the active substance infliximab.
Croatian: Remsima sadrži djelatnu tvar infliksimab.
English: Do not use the syringe if:
Croatian: Nemojte primijeniti štrcaljku:
English: Sorbitol content Remsima contains 45 mg sorbitol per 1 mL (in each 120 mg dose).
Croatian: Remsima sadrži 45 mg sorbitola u 1 ml (u jednoj dozi od 120 mg).
English: d p = 0.030 and <0.001 for the 3 mg/kg and 6 mg/kg treatment groups respectively vs. placebo + MTX.
Croatian: d p = 0,030 za skupinu koja je primala dozu od 3 mg/kg i p < 0,001 za skupinu koja je primala dozu od 6 mg/kg u usporedbi s placebo + MTX.
English: a Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who entered the open-label extension.
Croatian: a Podaci za 98. tjedan ispitivanja IMPACT uključuju i bolesnike koji su prebačeni sa liječenja placebom i one koji su primali infliksimab i ušli u fazu otvorenog ispitivanja.
English: • Adhesive bandage*
Croatian: • flaster*
English: What you need to know before you use Remsima 3.
Croatian: Što morate znati prije nego počnete primjenjivati lijek Remsima
English: Once you remove the cap, do not recap the pen.
Croatian: Nakon što uklonite zatvarač, nemojte ga ponovno vraćati na brizgalicu.
English: Complete fistula response (%)b a A ≥50% reduction from baseline in the number of draining fistulas over a period of ≥4 weeks.
Croatian: Odgovor fistula (%) a Potpuni odgovor fistula (%) b a Smanjenje početnog broja fistula iz kojih se cijedi sadržaj za ≥ 50% tijekom razdoblja od
English: Table 5 Effects on response and remission rate, data from ACCENT I (Week-2 responders)
Croatian: Učinci na stope odgovora i remisije, podaci iz ACCENT I (bolesnici s odgovorom u 2. tjednu)
English: “click” and the olive green plunger rod will begin to fill the window.
Croatian: Napomena: kad se počne ubrizgavanje čut ćete prvi glasni „klik“, a maslinastozeleni klip će početi ispunjavati stakleni prozorčić.
English: A reduction in signs and symptoms was defined to be at least a 20% improvement (ACR20) in both tender and swollen joint counts, and in 3 of the following 5 criteria: (1) evaluator's global assessment, (2) patient's global assessment, (3) functional/disability measure, (4) visual analogue pain scale and (5) erythrocyte sedimentation rate or C-reactive protein.
Croatian: Smanjenje znakova i simptoma bilo je definirano kao najmanje 20%-tno poboljšanje (ACR20) s obzirom na broj osjetljivih i otečenih zglobova te poboljšanje u 3 od sljedećih 5 kriterija: (1) općoj ocjeni ispitivača, (2) općoj ocjeni bolesnika, (3) mjerilu funkcije/ograničenja, (4)
English: In an exploratory clinical study involving patients with moderate to severe COPD who were either current smokers or ex-smokers, 157 adult patients were treated with infliximab.
Croatian: U eksplorativnom kliničkom ispitivanju u bolesnika sa srednje teškim do teškim KOPB-om koji su bili aktivni ili bivši pušači, 157 odraslih bolesnika liječilo se infliksimabom.
English: Infusion reactions following re-administration of infliximab
Croatian: Reakcije na infuziju nakon ponovne primjene lijeka infliksimab